Titration

Cell-based Assays Market worth $22.0 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, March 19, 2021
Natural sciences, Chemistry, Physical sciences, Assay, Biochemistry, Titration, Contract research organization

Based on product and service, the market is segmented into consumables, instruments & software, and services.

Key Points: 
  • Based on product and service, the market is segmented into consumables, instruments & software, and services.
  • Based on application, the cell based assays market is categorized into drug discovery, basic research, and other applications.
  • Based on end users, the cell based assays market is segmented into pharmaceutical & biopharmaceutical companies, academic & research institutes, and contract research organizations (CROs).
  • The cell-based assays market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA).

Altasciences Qualifies Quantitative Serological Assay for Detection of SARS-CoV-2 IgG Antibodies

Retrieved on: 
Wednesday, March 17, 2021
Professional services, Health, Clinical trials, Consulting, Pharmaceutical, Biotechnology, Natural sciences, Chemistry, Physical sciences, Laboratory techniques, Assay, Biochemistry, Titration, National Research Council Canada, Reporter virus particles, COVID-19 testing

Altasciences , working with the National Research Council of Canada (NRC), has qualified a quantitative serological assay for the detection of SARS-CoV-2 IgG antibodies, to support vaccine development in studies from discovery to Phase II.

Key Points: 
  • Altasciences , working with the National Research Council of Canada (NRC), has qualified a quantitative serological assay for the detection of SARS-CoV-2 IgG antibodies, to support vaccine development in studies from discovery to Phase II.
  • The assay was qualified in a GLP laboratory, using a source of spike protein that is reliably and robustly produced in Canada.
  • Altasciences worked with the NRC to test various antigens and select the best reagents for the assay.
  • For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions.

Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment

Retrieved on: 
Tuesday, March 16, 2021
Branches of biology, Natural sciences, Physical sciences, Laboratory techniques, Assay, Biochemistry, Titration, Irritation, Draize test

The EpiOcular TM MTT ET-50 risk assessment assay determines the effective time when a material causes a 50% reduction in the viability of tissue being assessed.

Key Points: 
  • The EpiOcular TM MTT ET-50 risk assessment assay determines the effective time when a material causes a 50% reduction in the viability of tissue being assessed.
  • Test materials are then categorized into one of four classifications, ranging from non-irritating to severe/extreme irritation, which correspond to groupings of the in vivo gold standard, the Draize eye test.
  • It is important to evaluate the irritation potential of a drug formulation in order to avoid exposing humans to potentially irritating materials during clinical testing and/or approved use.
  • Skye is currently advancing manufacturing and formulation work on THCVHS in preparation for entering the clinic later this year.

New Found Intercepts 24.0g/t over 46.0m and 27.0g/t over 30.1m at Keats, High-grade Gold Mineralization Discovered in Footwall Veins

Retrieved on: 
Wednesday, March 10, 2021
Chemistry, Physical sciences, Natural sciences, Laboratory techniques, Coins, Assay, Biochemistry, Titration, Gold, Metallurgical assay

The complete sample metallic screen assay method is selected by the geologist when samples contain coarse gold or any samples displaying gold initial fire assay values greater than 1.0 g/t Au.

Key Points: 
  • The complete sample metallic screen assay method is selected by the geologist when samples contain coarse gold or any samples displaying gold initial fire assay values greater than 1.0 g/t Au.
  • Standards and blanks are included with every 20 samples for Quality Assurance/Quality Control purposes by the Company as well as the lab.
  • Mr Matheson consents to the publication of this announcement dated March 10, 2021 by New Found Gold.
  • Our management has a pledge to be in touch with any investor inquiries within 24 hours.

Ellume and Cambridge Consultants Collaborate on Core Technology Behind Ellume’s Rapid Antigen COVID-19 Test

Retrieved on: 
Wednesday, March 10, 2021
Natural sciences, Assay, Biochemistry, Titration

Together, the two companies have developed a next-generation, multi-component reader that combines optics, electronics and software, and powers the core technology behind the Ellume COVID-19 Home Test.

Key Points: 
  • Together, the two companies have developed a next-generation, multi-component reader that combines optics, electronics and software, and powers the core technology behind the Ellume COVID-19 Home Test.
  • Without Cambridge Consultants and their continued partnership over the years, we wouldnt have been able to achieve technical success.
  • The impact of this technology extends beyond the Ellume COVID-19 Home Test, and even beyond the COVID-19 pandemic.
  • The company has also leveraged the core sensing breakthrough in its core technology for its rapid home flu test and diagnostic assay for tuberculosis.

Bruker and Visikol Partner to Launch Light-Sheet Imaging Services

Retrieved on: 
Tuesday, March 9, 2021
Natural sciences, Physical sciences, Chemistry, Laboratory techniques, Assay, Biochemistry, Titration, Pathology, Imaging, Medical imaging

Since its inception in 2016, Visikol has assisted thousands of researchers in transitioning from two-dimensional to three-dimensional imaging through its contract research services and Visikol HISTO reagents.

Key Points: 
  • Since its inception in 2016, Visikol has assisted thousands of researchers in transitioning from two-dimensional to three-dimensional imaging through its contract research services and Visikol HISTO reagents.
  • Visikol has already begun to offer these light-sheet imaging services to its clients at highly competitive rates for both industry customers and academic researchers.
  • To leverage light-sheet imaging, researchers can either send Visikol fixed tissues for clearing or already fixed, labeled, and cleared samples for imaging.
  • Visikol is a contract services company that is focused on accelerating drug discovery and development through the use of its imaging, digital pathology and advanced cell culture assay services.

FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay

Retrieved on: 
Monday, March 1, 2021
Laboratory techniques, Natural sciences, Chemistry, Physical sciences, Biotechnology, Molecular biology, Assay, Biochemistry, Titration, Reverse transcription polymerase chain reaction, Coronavirus disease, Nasopharyngeal swab

The kit is authorized for at-home self-collection by prescription only for individuals suspected of COVID-19 by their health care providers.

Key Points: 
  • The kit is authorized for at-home self-collection by prescription only for individuals suspected of COVID-19 by their health care providers.
  • The assay does not require collection via invasive nasopharyngeal swab, and the companys submission to the FDA demonstrated 100 percent agreement between saliva results from the Advanta Dx Assay and results from paired nasopharyngeal samples tested with authorized assays.
  • Fluidigm continually conducts in silico analyses to determine the effectiveness of the Advanta Dx Assay design to detect SARS-CoV-2.
  • The Advanta Dx SARS-CoV-2 RT-PCR Assay is only for use under the Food and Drug Administrations Emergency Use Authorization.

Global Apoptosis Assay Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report

Retrieved on: 
Thursday, February 25, 2021
Branches of biology, Biology, Natural sciences, Assay, Biochemistry, Titration, Apoptosis

8.3.1.

Key Points: 
  • 8.3.1.
  • Global Apoptosis Assay Market, by Pharmaceutical & Biotechnology Companies, By Region, 2016-2028 (USD Million)
    8.4.1.
  • Global Apoptosis Assay Market, by Hospital & Diagnostic Laboratories, by Region, 2016-2028 (USD Million)
    8.5.1.
  • Global Apoptosis Assay Market, by Academic & Research Institutes, by Region, 2016-2028 (USD Million)

Troubadour Reports Bonanza-Grade Gold Results from Phase 1 Rock Sampling at the Texas Project

Retrieved on: 
Thursday, February 25, 2021
Chemistry, Physical sciences, Natural sciences, Laboratory techniques, Protein methods, Assay, Biochemistry, Titration, Chromatin immunoprecipitation, Metallurgical assay

Two grab samples* from the Doorn returned greater than 100 g/t gold and 100 g/t silver; overlimit assay results are pending.

Key Points: 
  • Two grab samples* from the Doorn returned greater than 100 g/t gold and 100 g/t silver; overlimit assay results are pending.
  • A 0.25 m chip sample across a vein outside the Cabin adit returned 18.95 g/t gold.
  • Rediscovery of the Gold Bug workings 2 km southwest of the Doorn was confirmed by a 1.0 m chip sample that returned 8.19 g/t gold.
  • The most notable grab sample assay results from the 2020 Phase 1 exploration program are listed in the table below:

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

Retrieved on: 
Tuesday, February 23, 2021
Research, Medical devices, Infectious diseases, Genetics, Biotechnology, Other Health, Health, Science, Oncology, Natural sciences, Chemistry, Physical sciences, Laboratory techniques, Assay, Biochemistry, Titration, Epidermal growth factor receptor, Non-small-cell lung carcinoma

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will collaborate with Protean BioDiagnostics Inc. to research the ability of Biocepts Target Selector molecular assay to determine EGFR status in non-small cell lung cancer (NSCLC) patients.

Key Points: 
  • Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will collaborate with Protean BioDiagnostics Inc. to research the ability of Biocepts Target Selector molecular assay to determine EGFR status in non-small cell lung cancer (NSCLC) patients.
  • We are pleased to collaborate with Biocept to demonstrate the potential of its assay in determining EGFR status, said Anthony M. Magliocco, MD, President and CEO of Protean BioDiagnostics.
  • Together, our goal is to demonstrate how Target Selector assays can help physicians create more personalized, responsive treatment plans for their patients.
  • For more information on Biocept's Target Selector molecular assay kits, contact Biocept Customer Service at (888) 332-7729 or [email protected] .